Biotech Values

[DewDiligence]

SLRX reverse-merges with—(private)—Decoy Therapeutics:

https://www.globenewswire.com/news-release/2025/01/13/3008457/0/en/Salarius-Pharmaceuticals-and-Decoy-Therapeutics-Announce-Definitive-Merger-Agreement.html

…it is expected that following closing and a post-closing stockholder vote to approve the conversion of the preferred shares into common stock, Decoy investors would own approximately 86% of the outstanding shares of the merged company and Salarius stockholders would own approximately 14% of the outstanding shares…

… Decoy Therapeutics is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The company’s initial pipeline is focused on respiratory viruses and GI cancers.

SLRX is itself the product of a reverse-merger in 2019 (#msg-145871960).